Tuomas R. Holmberg
Fundador en NovaDigm Therapeutics, Inc. .
Cargos activos de Tuomas R. Holmberg
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Director/Miembro de la Junta | 01/01/2005 | - |
| Fundador | 01/01/2005 | - | |
| Corporate Officer/Principal | 01/01/2005 | - |
Historial de carrera de Tuomas R. Holmberg
Antiguos cargos conocidos de Tuomas R. Holmberg.
| Empresas | Cargo | Inicio | Fin |
|---|
Formación de Tuomas R. Holmberg.
| University of Southern California | Masters Business Admin |
| California Institute of Technology | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
Operativa
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
- Bolsa de valores
- Insiders
- Tuomas R. Holmberg
- Experiencia
